Department of Radiology, Nara Medical University, Nara, Japan.
Anticancer Res. 2012 Sep;32(9):4121-4.
Hepatic arterial infusion chemotherapy (HAIC) combined with sorafenib is considered to be a promising therapeutic strategy for patients with advanced hepatocellular carcinoma. However, this combination therapy carries the risk of hepatic arterial thrombosis (HAT), which interrupts the continuation of HAIC, due to the side-effects of sorafenib. This case demonstrates a complication of HAT which occurred during HAIC combined with sorafenib. HAT was detected early by angiography via an implantable port-catheter system and was successfully treated with catheter-directed thrombolysis.
肝动脉灌注化疗(HAIC)联合索拉非尼被认为是治疗晚期肝细胞癌患者的一种有前途的治疗策略。然而,由于索拉非尼的副作用,这种联合治疗有发生肝动脉血栓形成(HAT)的风险,这会中断 HAIC 的继续进行。本病例报告了 HAIC 联合索拉非尼治疗过程中发生的 HAT 并发症。通过植入式端口导管系统进行血管造影早期发现 HAT,并成功进行了导管定向溶栓治疗。